Effects of Iloprost on Hypoxic Pulmonary Vasoconstriction at Altitude

Withdrawn before enrolling · Phase 1 · Has a placebo group

Conditions studied: Hypoxic Pulmonary Vasoconstriction

In brief

The objective of this study is to determine if single dose administration of inhaled iloprost will reduce pulmonary artery pressure, reduce hypoxic pulmonary vasoconstriction and improve arterial oxygenation at rest and during exercise at high altitude.

Key facts

Study ID

NCT00724321

Run by

Loma Linda University

People needed

0

Starts

2008-07-01

Expected to finish

2008-11-01

Last updated by the study team

2015-09-18

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Age: 18 - 80 years
• Healthy physically active males or females
• Have readily measurable tricuspid regurgitation (TR) peak systolic velocity by continuous wave Doppler ultrasound

You may not qualify if…

• Known liver disease
• Pregnancy
• Medications that in the opinion of the investigators could place subjects at increased risk of complications Any other medical condition that in the opinion of the investigators would place the subject at high risk

Where it is running

• Loma Linda University — Loma Linda, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.